Modern Dental Europe Ltd. has acquired Permadental Holding B.V. from Foreman Capital
Modern Dental Europe Ltd. (MDL) has acquired Permadental Holding B.V. (Permadental) from Foreman Capital.
MDL produces dental prosthesis for dentists and doctors around the world. The company is part of the Modern Dental Holding Ltd group, one of the largest dental laboratories in the world, with production facilities in Shenzhen, China.
Permadental is the importer and supplier of dental prosthesis in the German market. The company has a track record of serving dentists for over 25 years by supplying them with crowns, bridges, implants and telescopic crowns, all manufactured in China.
Founded by Arent Foch and Guido ter Kuile in 2005, Foreman Capital is an independent investment company focused on investments in European companies that are active in trade, manufacturing and service provision.
Oaklins' team in the Netherlands advised the buyer in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more